Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LHT344 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| LHT344 | DRUG | - |
Inclusion Criteria: * Healthy, non-smoking, male or female subjects age 18 to 45 years of age * In good health as confirmed by past medical history, physical examination, electrocardiogram, laboratory tests and urinalysis on the screening and baseline evaluation * Body mass index within the range o...
LHT344 is an investigational small molecule developed by Novartis AG. It has been studied in a Phase 1 clinical trial in Chinese healthy subjects, where researchers evaluated its safety and pharmacokinetics. The specific disease or condition LHT344 is intended to treat has not been disclosed, and the compound remains in early clinical development.
LHT344 is being developed by Novartis AG, which trades on the New York Stock Exchange under the ticker NVS. The company sponsored the Phase 1 study of LHT344 conducted in China. No partnership or licensing arrangement for the asset has been announced.
LHT344 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The study enrolled 12 healthy volunteers in China. LHT344 is investigational and has not been approved by the FDA or any other regulatory agency for any indication.
LHT344 has been evaluated in one completed Phase 1 trial, NCT00414778, titled Safety and Pharmacokinetics of LHT344 in Chinese Healthy Subjects. The study enrolled 12 healthy adult volunteers of all sexes, aged 18 years and older, in China. It was an uncontrolled, non-randomized, open-label design.
The molecular target of LHT344 has not been disclosed. LHT344 is a small molecule, and its Phase 1 trial in healthy subjects assessed safety and pharmacokinetics rather than target engagement. No biomarker-selected population was used in the study, and no target or mechanism information has been released by the developer.